Viridian Therapeutics (VRDN) 10-Q 15 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	8-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	SIGNAL GENETICS, INC.
Document Type	10-Q
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		7,757,904
Amendment Flag	FALSE
Entity Central Index Key	1590750
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash	$13,268	$5,119
Accounts receivable, net	598	1,088
Inventory	330	179
Prepaid expenses and other current assets	295	399
Total current assets	14,491	6,785
Property and equipment, net	1,213	1,214
Deferred offering costs		47
Security deposits	43	43
Total assets	15,747	8,089
Current liabilities:
Accounts payable	384	255
Accrued liabilities	803	361
Note payable – related party	1,058
Amounts due to related party		1,045
Lease termination/abandonment payable - current portion	156	248
Other current liabilities	94	80
Total current liabilities	2,495	1,989
Other noncurrent liabilities	103	109
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding at March 31, 2015 or December 31, 2014	0	0
Common stock, $0.01 par value, 50,000,000 shares authorized, 7,504,990 and 3,782,629 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively	75	38
Additional paid in capital	22,348	12,593
Accumulated deficit	-9,274	-6,640
Total stockholders’ equity	13,149	5,991
Total liabilities and stockholders’ equity	$15,747	$8,089

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Preferred stock par value (in Dollars per share)	$0.01	$0.01
Preferred stock shares authorized	5,000,000	5,000,000
Preferred stock shares issued	0	0
Preferred stock outstanding	0	0
Common stock par value (in Dollars per share)	$0.01	$0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	7,504,990	3,782,629
Common stock, shares outstanding	7,504,990	3,782,629

Unaudited_Condensed_Consolidat

Unaudited Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net revenue	$645	$1,091
Operating expenses:
Cost of revenue	760	731
Research and development	100	35
Selling and marketing	434	66
General and administrative	1,963	426
Total operating expenses	3,257	1,258
Loss from operations	-2,612	-167
Interest expense	-22	-539
Net loss	-2,634	-706
Net loss per common share, basic and diluted (in Dollars per share)	($0.45)	($3.53)
Weighted-average number of shares outstanding, basic and diluted (in Shares)	5,793,082	200,000
Successor [Member]
Operating expenses:
Net loss	-2,634
Predecessor [Member]
Operating expenses:
Net loss		($706)

Unaudited_Condensed_Consolidat1

Unaudited Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
OPERATING ACTIVITIES
Net loss	($2,634)	($706)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation	708
Depreciation and amortization	45	36
Noncash interest on note payable – related party	20	532
Accounts receivable	490	-180
Inventory	-151	232
Prepaid expenses and other current assets	104	311
Accounts payable and other current liabilities	401	9
Lease termination/abandonment payable	-92	-149
Net cash provided by (used in) operating activities	-1,109	85
INVESTING ACTIVITIES
Purchases of property and equipment	-44
Net cash used in investing activities	-44
FINANCING ACTIVITIES
Proceeds from issuance of common stock, net of costs to issue	9,346	-274
Proceeds from issuance of note payable/amounts due to related party		100
Shares repurchased to satisfy tax withholding obligation for restricted stock award	-27
Repayment of capital lease obligation and note payable	-17	-15
Net cash provided by (used in) financing activities	9,302	-189
Net increase (decrease) in cash	8,149	-104
Cash, beginning of period	5,119	209
Cash, end of period	$13,268	$105

Note_1_Basis_of_Presentation

Note 1 - Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Business Description and Basis of Presentation [Text Block]	1.	Basis of Presentation
	Signal Genetics, Inc. (the “Company”) is a commercial stage, molecular genetic diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. In 2010, the Company became the exclusive licensee to the intellectual property stemming from the renowned research on multiple myeloma (“MM”), performed at the University of Arkansas for Medical Sciences (“UAMS”). Myeloma Prognostic Risk Signature (“MyPRS®”) is based upon 30 years of clinical research on over 10,000 MM patients who received their care at UAMS. The Company currently generates revenues from the performance of its MyPRS® diagnostic tests, which was launched in April 2011.
	Basis of Presentation and Liquidity
	The accompanying consolidated financial statements include the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
	Since its inception, the Company has devoted substantial effort in developing its products and services and has incurred losses and negative cash flows from operations. Prior to its IPO, all financial support had been provided by the Company’s majority member. As of March 31, 2015, however, following the 2015 Offering, the Debt Conversion, the Corporate Conversion and the IPO, each as defined below, the Company has positive working capital and stockholders’ equity. Although the Company is forecasting continued losses and negative cash flows as it funds its expanding selling and marketing activities, and research and development programs, the Company believes that it has enough cash on hand to support operations for at least the next year. Going forward, as the Company continues its expansion, it may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company’s ability to achieve its intended business objectives. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
	The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles have been omitted. The accompanying unaudited consolidated financial statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by accounting principles generally accepted in the United States. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Actual results may materially differ from these estimates. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. The consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2014, which are included in the Company’s Annual Report on Form 10-K filed with the SEC on March 27, 2015.
	Public Offering of Common Stock
	On February 20, 2015, the Company completed a public offering (the “2015 Offering”) of 3,214,285 shares of its common stock, at $2.80 per share, for total cash proceeds of $7.9 million, which is net of $1.1 million in underwriter commissions and offering expenses. On February 26, 2015, the underwriters exercised their overallotment option for 482,142 additional shares of the Company’s common stock, for total cash proceeds of $1.3 million, which is net of $95,000 in underwriter commissions.
	Corporate Conversion and Initial Public Offering
	On June 17, 2014, the Company completed a corporate conversion and Signal Genetics LLC converted from a limited liability company to a Delaware corporation (the “Corporate Conversion”). Immediately prior to the Corporate Conversion, $27.3 million of the Company’s note payable — related party was converted into 2,732,629 newly authorized Class C units (the “Debt Conversion”). In connection with the Corporate Conversion, all outstanding Class A and C units of Signal Genetics LLC were converted into 200,000 and 2,732,629 shares, respectively, for an aggregate of 2,932,629 shares of common stock of the Company, the members of Signal Genetics LLC became stockholders of the Company and the Company succeeded to the business of Signal Genetics LLC and its consolidated subsidiaries.
	On June 23, 2014, the Company completed an initial public offering (the “IPO”) of 850,000 shares of its common stock, at $10.00 per share, for net cash proceeds of $6.1 million, which is net of $2.4 million in underwriter commissions and offering expenses. The net contribution to additional paid-in capital was $5.8 million after deducting the noncash fair values of warrants and option for overallotment shares issued in connection with the IPO.

Note_2_Significant_Accounting_

Note 2 - Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2.	Significant Accounting Policies
	Use of Estimates
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make judgments, assumptions and estimates that affect the amounts reported in the Company’s consolidated financial statements and accompanying notes. Significant estimates in the consolidated financial statements have been made for revenue, depreciation of property and equipment and stock-based compensation. Actual results could differ materially from those estimates.
	Cash
	The Company considers all highly liquid investments with a maturity at date of purchase of three months or less to be cash equivalents. Cash is currently comprised only of cash on hand and deposits in banks. At March 31, 2015 and December 31, 2014, the Company had $50,000 in a restricted money market account that was held as cash collateral against an outstanding letter of credit for security on a lease.
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable are recorded net of an allowance for doubtful accounts. The Company estimates an allowance for doubtful accounts based on the aging of the accounts receivable and the historical collection experience for each type of payor. Account balances are charged-off against the allowance when it is probable the receivable will not be recovered.
	During the three months ended March 31, 2015 and 2014, the Company recognized $24,000 and $0 in bad debt expense, respectively. At March 31, 2015 and December 31, 2014, the allowances for doubtful accounts were $20,000 and $0, respectively.
	Inventory
	Inventory, which consists entirely of raw materials, and includes laboratory materials and supplies, is valued at the lower of cost or market using the first-in, first-out (“FIFO”) method.
	Deferred Offering Costs
	During the year ended December 31, 2014, the Company incurred $47,000 in direct costs related to its anticipated public offering of common stock. These costs were deferred and recorded as a long-term asset at December 31, 2014 and reclassified as a reduction to additional paid-in capital upon completion of the 2015 Offering.
	Revenue Recognition
	Revenues that are derived from testing services are recognized in accordance with revenue recognition accounting guidance, which requires that four basic criteria be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured.
	Revenues are recorded on an accrual basis when the contractual obligations are completed as tests are processed through the Company’s laboratory and test results are delivered to ordering physicians. Revenues are billed to various payors, including Medicare, contracted insurance companies, directly billed customers (UAMS, pharmaceutical companies, reference laboratories and hospitals) and non-contracted insurance companies. Revenues from Medicare, contracted insurance companies and directly billed customers are reported based on the contractual rate. The difference between the amounts billed and the contractual rates from Medicare and contracted insurance companies are recorded as contractual allowances at the same time the revenue is recognized, to arrive at reported net revenue. The contractual rate is based on established agreed upon rates between the Company and the respective payor. Directly billed customers are invoiced the contractual rate by the Company. Revenues from non-contracted insurance companies are reported based on the amount expected to be collected, which is based on the historical collection experience of each payor or payor group, as appropriate, and anticipated effects of changes in the healthcare industry, if any. The difference between the amount billed and the amount estimated to be collected from non-contracted insurance companies is recorded as a contractual allowance at the same time the revenue is recognized, to arrive at reported net revenue. The Company does not record revenue from individuals for billings until cash is collected; as collectability is not assured at the time services are provided, therefore there are no accounts receivable from self-payors. Gross revenues from individuals have been immaterial to date.
	The Company’s estimates of net revenue for non-contracted insurance companies are subject to change based on the contractual status and payment policies of the third-party payors with whom the Company deals. The Company regularly refines its estimates in order to make estimated revenue as accurate as possible based on its most recent collection experience with each third-party payor. The Company regularly reviews its historical collection experience for non-contracted payors and anticipated changes in the healthcare industry and adjusts expected revenues for current and subsequent periods accordingly. During the three months ended March 31, 2015, net unfavorable changes in estimates were recorded to revenue related to non-contracted revenues recorded in the prior year of $30,000.
	The table below shows the adjustments made to gross revenues to arrive at net revenues, the amount reported in the consolidated statements of operations:
			Three Months Ended March 31,
	(in thousands)		2015			2014
	Gross revenues		$	1,317		$	1,484
	Less: contractual allowances			(672	)		(393	)
	Net revenue		$	645		$	1,091
	Contractual allowances recorded during the three months ended March 31, 2015 and 2014 represented 51% and 26% of gross revenues, respectively. The increase in the contractual allowances is due to changes in our estimates of net revenue for non-contracted payors based on the contractual status and payment policies of the payors, and anticipated changes in the healthcare industry.
	Stock-Based Compensation
	Compensation expense for all stock-based payments made to employees, directors, and consultants are measured and recognized based on estimated fair value, net of an estimated forfeiture rate. These stock-based awards include stock options and restricted stock units. The Company estimates the fair value of stock options granted using the Black-Scholes-Merton (“BSM”), option-pricing model, which requires the use of estimates such as stock price volatility and expected option lives, as well as expected option forfeiture rates. The fair value of stock options granted to employees is estimated at the date of grant, while the fair value of stock options granted to non-employees is estimated at the date of grant using the BSM pricing model and remeasured at each subsequent reporting date to fair value until performance is complete, with changes in fair value recognized as expense in the statement of operations.
	The fair value of restricted stock units issued to employees is based on the market price of the Company’s common stock on the date of grant and, for nonemployees, at the date when performance is complete. Upon settlement of all or a portion of the award in cash, the recognized fair value of the corresponding amount of awards is reversed from additional paid-in capital and the excess of the cash payment over this amount is recognized as additional stock-based compensation expense.
	Stock-based compensation cost is recognized on a straight-line basis over the requisite service period of the award. Stock-based compensation expense is recognized only for those awards that are ultimately expected to vest. The Company estimates forfeitures at the time of grant and revises the estimate, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Changes in forfeiture estimates impact compensation cost in the period in which the change in estimate occurs.
	Due to the Company’s net loss position, no tax benefits for stock-based compensation have been recognized in the statements of cash flows. The Company has not recognized, and does not expect to recognize in the near future, any tax benefit related to stock-based compensation cost as a result of its full valuation allowance on net deferred tax assets and net operating loss carryforwards.
	Fair Value of Financial Instruments
	The Company’s financial instruments that are measured at fair value on a recurring basis consist principally of cash, restricted cash, accounts receivable and accounts payable
	The carrying amounts of financial instruments such as accounts receivable and accounts payable approximate their relative fair values due to the short-term maturities of these instruments.
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
	Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
	Level 2—Includes other inputs that are directly or indirectly observable in the marketplace.
	Level 3—Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own assumptions.
	Net Loss Per Share
	Basic and diluted net loss per common share for the periods presented is computed by dividing net loss by the weighted-average number of common shares outstanding during the respective periods, without consideration of common stock equivalents. Basic and diluted net loss per common share includes vested, but unissued restricted stock units from the date of vesting.
	Common stock equivalents that could potentially reduce net income per common share in the future that were not included in the determination of diluted loss per common share as their effects were antidilutive are as follows:
			March 31,
			2015
	Unvested restricted stock units			527,934
	Options to purchase common stock			180,000
	Warrants to purchase common stock			203,214
	Total			911,148
	Concentration of Credit Risk, Major Customers and Suppliers
	Cash is maintained at two financial institutions and, at times, balances may exceed federally insured limits. The Company has not experienced any losses related to these balances.
	During the three months ended March 31, 2015 and 2014, the Company had one major customer, UAMS. Revenue sourced either from or through UAMS accounted for 77% and 79% of net revenue during the three months ended March 31, 2015 and 2014, respectively. Accounts receivable sourced either from or through UAMS at March 31, 2015 and December 31, 2014 accounted for 58% and 63% of total accounts receivable outstanding, respectively.
	Inventory used in the Company’s testing process is procured from one supplier. Any supply interruption or an increase in demand beyond such supplier’s capabilities could have an adverse impact on the Company’s business. Management believes it could identify alternative suppliers, if necessary, but it is possible such suppliers may not be identified in a timely manner to avoid an adverse impact on the Company’s business.
	Reclassifications
	Reclassifications of certain operating expenses in the consolidated statement of operations have been made as of and during the three months ended March 31, 2014 to conform to the 2015 presentation.
	Recent Accounting Pronouncements
	In February 2015, the Financial Accounting Standards Board (“FASB”) issued amendments to Accounting Standards Update (“ASU”) 2015-02, Consolidation: Amendments to the Consolidation Analysis. This standard simplifies consolidation accounting by reducing the number of consolidation models and changing various aspects of current GAAP, including certain consolidation criteria for variable interest entities. This standard becomes effective for the Company’s first quarter beginning January 1, 2017 with early adoption permitted. Upon adoption, the Company may elect prospective or retrospective application. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
	In January 2015, the FASB issued ASU 2015-01, Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items. Under this standard, an entity will no longer be allowed to separately disclose extraordinary items, net of tax, in the income statement after income from continuing operations if an event or transaction is unusual in nature and occurs infrequently. This standard becomes effective for the Company’s first quarter beginning January 1, 2016 with early adoption permitted. Upon adoption, the Company may elect prospective or retrospective application. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which outlines a single comprehensive model for entities to use in accounting for revenue from contracts with customers and supersedes most current revenue recognition guidance in FASB ASC 605, Revenue Recognition, including industry-specific guidance. This standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This standard also requires additional disclosure about the nature, amount, timing and uncertainty of assets recognized from costs incurred to fulfill a contract and becomes effective for the Company’s annual reporting period beginning January 1, 2019, including interim periods within that reporting period; early adoption is not permitted. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements — Going Concern, which provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and the related footnote disclosure. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financials are issued. When management identifies conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern, this standard also outlines disclosures that are required in the company’s footnotes based on whether or not there are any plans intended to mitigate the relevant conditions or events to alleviate the substantial doubt. This standard becomes effective for the Company’s annual reporting period ending December 31, 2016, and for annual and interim periods thereafter. Early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

Note_3_Balance_Sheet_Accounts_

Note 3 - Balance Sheet Accounts and Supplemental Disclosures	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block Supplement [Abstract]
Supplemental Balance Sheet Disclosures [Text Block]	3.	Balance Sheet Accounts and Supplemental Disclosures
	Property and Equipment
	Property and equipment consist of the following:
	(in thousands)		March 31,			31-Dec-14
			2015
	Laboratory and computer equipment		$	1,745		$	1,711
	Furniture and fixtures			62			52
	Leasehold improvements			6			6
				1,813			1,769
	Less: accumulated depreciation and amortization			(600	)		(555	)
	Total property and equipment, net		$	1,213		$	1,214
	An asset with a cost of $300,000 recorded under a capital lease is included in the laboratory equipment balances at March 31, 2015 and December 31, 2014.
	Accrued Expenses
	Accrued expenses consist of the following:
	(in thousands)		March 31,			31-Dec-14
			2015
	Accrued compensation and related expenses		$	483		$	257
	Accrued offering costs			225			42
	Other			95			62
	Total accrued expenses		$	803		$	361

Note_4_Note_Payable_Related_Pa

Note 4 - Note Payable - Related Party, Amount Due Related Party and Capital Lease Obligations	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block Supplement [Abstract]
Debt and Capital Leases Disclosures [Text Block]	4.	Note Payable – Related Party, Amount Due Related Party and Capital Lease Obligations
	Note Payable — Related Party and Amounts Due to Related Party
	On March 6, 2015, the amounts due to related party aggregating $1,045,000 were converted into an unsecured note payable – related party bearing interest at 8% per annum and due on demand. The principal amount of the note was increased by $60,000 over the amounts due to related party to $1,105,000 to provide the equivalent of 8% per annum interest for the period of time the amounts due to related party were held as a payable in exchange for a provision that the related party would not call the note prior to June 30, 2015. The increase in the principal amount of the note has been deferred and is amortized to interest expense over the initial term of the note to June 30, 2015. The note balance at March 31, 2015 was $1,058,000, which is net of $47,000 in the remaining unamortized discount. Interest expense related to this note during the three months ended March 31, 2015 was $19,000, and is included in the note payable-related party balance reporting in the consolidated balance sheet at March 31, 2015.
	During the three months ended March 31, 2014, the Company’s then majority member, through various entities controlled by such member, loaned a net amount of $100,000, to the Company to support its operations. The average amount of borrowings under this note, which bore interest at 8% compounded quarterly and was due on demand, during the three months ended March 31, 2014, was $26.9 million. This note was subsequently converted into equity in June 2014. Interest expense related to this note during the three months ended March 31, 2014 was $532,000.
	Capital Lease Obligation
	In December 2014, the Company entered into a new two-year capital lease obligation for laboratory equipment which expires in January 2017, and provides for monthly rent of $7,200. The lease obligation at March 31, 2015 and December 31, 2014 aggregated $148,000 and $164,000, which is net of $7,000 and $8,000 in unamortized discounts, respectively. Future maturities of this obligation at March 31, 2015 are $65,000 during the remainder of 2015 and $86,000 and $4,000 during 2016 and 2017, respectively.

Note_5_Stockholders_Equity

Note 5 - Stockholders’ Equity	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	5.	Stockholders’ Equity
	Changes in common shares outstanding and total stockholders’ equity during the three months ended March 31, 2015 were as follows:
			Shares of Common Stock			Total Stockholders’ Equity
						(in thousands)
	Balance, December 31, 2014			3,782,629		$	5,991
	Public offering of common shares, net of costs to issue			3,696,427			8,781
	Fair value of warrants and option to underwriters for overallotment shares issued in connection with public stock offering			—			330
	Stock-based compensation			—			708
	Shares issued under employee stock incentive plan, net of shares withheld to satisfy tax withholding obligations			25,934			(27	)
	Net loss			—			(2,634	)
	Balance, March 31, 2015			7,504,990		$	13,149
	Common Shares
	The Company has authorized 50,000,000 shares of common stock, of which 7,504,990 shares were issued and outstanding at March 31, 2015. Common shares reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at March 31, 2015 is as follows:
	Issued and Outstanding:
	Restricted stock units			903,704
	Stock options			180,000
	Warrants			203,214
	Shares reserved for future award grants			135,761
	Total			1,422,679
	Public Offering of Common Stock
	On February 20, 2015, the Company completed a public offering of 3,214,285 shares of its common stock, at $2.80 per share, for total cash proceeds of $7.9 million, which is net of $1.1 million in underwriter commissions and offering expenses. In connection with the offering, the Company granted a 45-day option to the underwriter to purchase up to 482,142 shares of common stock to cover overallotments, with an aggregate grant date fair value of $132,000. On February 26, 2015, the underwriters exercised the overallotment option for total cash proceeds of $1.3 million, which is net of $95,000 in underwriter commissions. In connection with this offering, as a portion of the underwriting compensation payable to the underwriters, the Company issued warrants to purchase 160,713 shares of its common stock to the representative of the underwriters with an aggregate grant date fair value of $198,000. The warrants are exercisable at any time from February 2016 through February 2020 at an exercise price of $3.50 per share. The aggregate fair values of the warrants and overallotment option issued were recorded as an increase to additional paid-in capital with an offset to the proceeds from the offering. The net contribution to additional paid-in capital was $8.8 million after deducting the noncash fair values of warrants and overallotment option issued in connection with the offering.
	The estimated fair values of the warrants and overallotment option were determined on their respective measurement dates using the BSM option valuation model with the following assumptions:
			Warrants			Overallotment Option
	Fair value of underlying common stock		$	2.57		$	2.62
	Exercise price		$	3.5		$	2.6
	Risk-free interest rate			1.61	%		0.02	%
	Volatility			65.5	%		73	%
	Dividend Yield			0	%		0	%
	Contractual term (in years)			5			0.12
	Weighted-average measurement date fair value per share		$	1.23		$	0.27

Note_6_Stock_Compensation_Plan

Note 6 - Stock Compensation Plan	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	6.	Stock Compensation Plan
	The Company’s 2014 Stock Incentive Plan (the “Plan”) provides for stock awards that may be made in the form of incentive or non-statutory stock options, stock appreciation rights, restricted or unrestricted stock awards, restricted stock units, performance awards, or other stock-based awards. No awards may be granted after June 16, 2024. At March 31, 2015, awards for up to 1,219,465 shares of common stock may be issued under the Plan, of which 1,083,704 shares are reserved for issuance upon the exercise of outstanding options and vesting of outstanding restricted stock units, and 135,761 shares are available for future grants.
	Restricted Stock Units (“RSUs”)
	All of the Company’s outstanding RSU agreements provide for the settlement of the vested RSUs in shares of the Company’s common stock equal to the number of vested RSUs or an amount in cash equal to the product of the fair market value of the common stock on the respective payment date and the number of vested RSUs, or some combination of common shares and cash as determined by the plan administrator as of each settlement date.
	RSUs generally vest over a period of one to four years, subject to earlier cancellation or forfeiture prior to vesting upon cessation of service to the Company. A summary of the activity related to RSUs during the three months ended March 31, 2015 is as follows:
			Number of Shares			Weighted-Average Grant Date Fair Value per Share
	Unvested at December 31, 2014			655,200		$	9.2
	Vested during the period			(127,266	)	$	10
	Unvested at March 31, 2015			527,934		$	9.01
	The total fair value of RSUs that vested during the three months ended March 31, 2015 was $322,000. As permitted under the Plan, the Company repurchased 10,455 shares with an aggregate value of $27,000 during the three months ended March 31, 2015 to satisfy tax withholding obligations for an employee in connection with the vesting of restricted stock units previously granted to him.
	Stock Options
	Stock options generally vest over a four-year period and have a maximum term of ten years from the date of grant, subject to earlier cancellation prior to vesting upon cessation of service to the Company. A summary of the activity related to stock option awards during the three months ended March 31, 2015 is as follows:
			Shares Subject to Options			Weighted-Average Exercise Price per Share		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value
								(in years)		(in thousands)
	Outstanding at December 31, 2014			152,000		$	4.53
	Granted			29,000		$	2.44
	Forfeitures and cancellations			(1,000	)	$	5.6
	Outstanding at March 31, 2015			180,000		$	4.19		3.5	$	—
	Options exercisable at March 31, 2015			—		$	—		—	$	—
	Options vested or expected to vest at March 31, 2015			173,879		$	4.19		3.5	$	—
	Stock-Based Compensation Expense
	Compensation expense for time-based RSUs is measured using the fair value of the Company’s common stock on the date of grant and recognized ratably over the vesting period.
	The estimated fair value of each stock option award was determined on the date of grant using the BSM option valuation model with the following assumptions for the option grants during the three months ended March 31, 2015:
	Risk-free interest rate		1.34%	-	1.83%
	Expected volatility		65.30%	-	67.80%
	Weighted-average volatility			65.90%
	Dividend yield			0%
	Expected term (in years)			6.3
	Weighted-average grant date fair value per share			$1.49
	The fair value of each stock option is estimated on the date of grant using the BSM option pricing model which requires the input of highly subjective assumptions. Because the option-pricing model is sensitive to change in the input assumptions, different determinations of the required inputs may result in different fair value estimates of the options. The risk-free interest rate is based on the rate currently available on U.S. Treasury issues with terms approximating the expected term of the option. Due to the Company’s limited historical stock data, the estimated future stock price volatility is based upon the average historical volatilities of a group of peer companies. The Company has not paid any dividends on common stock since the Corporate Conversion and does not anticipate paying dividends on common stock in the foreseeable future. The Company did not issue options prior to the IPO and, therefore, has no history of option exercises. As such, the ‘simplified’ method has been used to estimate the expected term of options.
	Stock-based compensation expense is recognized only for those awards that are ultimately expected to vest. Forfeitures are required to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. A forfeiture rate of 1.9% was applied to options held by nonexecutives during the three months ended March 31, 2015.
	Total non-cash stock-based compensation expense for all stock awards that was recognized in the consolidated statements of operations during the three months ended March 31, 2015 is as follows:
	(in thousands)
	Cost of revenue		$	22
	Research and development			16
	Selling and marketing			11
	General and administrative			659
	Total		$	708
	At March 31, 2015, there was $3.6 million of unamortized compensation cost related to unvested RSUs which is expected to be recognized over a remaining weighted-average vesting period of 1.8 years. At March 31, 2015, there was $407,000 of unamortized compensation cost related to unvested stock option awards, which is expected to be recognized over a remaining weighted-average vesting period of 3.5 years.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make judgments, assumptions and estimates that affect the amounts reported in the Company’s consolidated financial statements and accompanying notes. Significant estimates in the consolidated financial statements have been made for revenue, depreciation of property and equipment and stock-based compensation. Actual results could differ materially from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash
	The Company considers all highly liquid investments with a maturity at date of purchase of three months or less to be cash equivalents. Cash is currently comprised only of cash on hand and deposits in banks. At March 31, 2015 and December 31, 2014, the Company had $50,000 in a restricted money market account that was held as cash collateral against an outstanding letter of credit for security on a lease.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable are recorded net of an allowance for doubtful accounts. The Company estimates an allowance for doubtful accounts based on the aging of the accounts receivable and the historical collection experience for each type of payor. Account balances are charged-off against the allowance when it is probable the receivable will not be recovered.
	During the three months ended March 31, 2015 and 2014, the Company recognized $24,000 and $0 in bad debt expense, respectively. At March 31, 2015 and December 31, 2014, the allowances for doubtful accounts were $20,000 and $0, respectively.
Inventory, Policy [Policy Text Block]	Inventory
	Inventory, which consists entirely of raw materials, and includes laboratory materials and supplies, is valued at the lower of cost or market using the first-in, first-out (“FIFO”) method.
Deferred Charges, Policy [Policy Text Block]	Deferred Offering Costs
	During the year ended December 31, 2014, the Company incurred $47,000 in direct costs related to its anticipated public offering of common stock. These costs were deferred and recorded as a long-term asset at December 31, 2014 and reclassified as a reduction to additional paid-in capital upon completion of the 2015 Offering.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition
	Revenues that are derived from testing services are recognized in accordance with revenue recognition accounting guidance, which requires that four basic criteria be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured.
	Revenues are recorded on an accrual basis when the contractual obligations are completed as tests are processed through the Company’s laboratory and test results are delivered to ordering physicians. Revenues are billed to various payors, including Medicare, contracted insurance companies, directly billed customers (UAMS, pharmaceutical companies, reference laboratories and hospitals) and non-contracted insurance companies. Revenues from Medicare, contracted insurance companies and directly billed customers are reported based on the contractual rate. The difference between the amounts billed and the contractual rates from Medicare and contracted insurance companies are recorded as contractual allowances at the same time the revenue is recognized, to arrive at reported net revenue. The contractual rate is based on established agreed upon rates between the Company and the respective payor. Directly billed customers are invoiced the contractual rate by the Company. Revenues from non-contracted insurance companies are reported based on the amount expected to be collected, which is based on the historical collection experience of each payor or payor group, as appropriate, and anticipated effects of changes in the healthcare industry, if any. The difference between the amount billed and the amount estimated to be collected from non-contracted insurance companies is recorded as a contractual allowance at the same time the revenue is recognized, to arrive at reported net revenue. The Company does not record revenue from individuals for billings until cash is collected; as collectability is not assured at the time services are provided, therefore there are no accounts receivable from self-payors. Gross revenues from individuals have been immaterial to date.
	The Company’s estimates of net revenue for non-contracted insurance companies are subject to change based on the contractual status and payment policies of the third-party payors with whom the Company deals. The Company regularly refines its estimates in order to make estimated revenue as accurate as possible based on its most recent collection experience with each third-party payor. The Company regularly reviews its historical collection experience for non-contracted payors and anticipated changes in the healthcare industry and adjusts expected revenues for current and subsequent periods accordingly. During the three months ended March 31, 2015, net unfavorable changes in estimates were recorded to revenue related to non-contracted revenues recorded in the prior year of $30,000.
	The table below shows the adjustments made to gross revenues to arrive at net revenues, the amount reported in the consolidated statements of operations:
		Three Months Ended March 31,
	(in thousands)	2015			2014
	Gross revenues	$	1,317		$	1,484
	Less: contractual allowances		(672	)		(393	)
	Net revenue	$	645		$	1,091
	Contractual allowances recorded during the three months ended March 31, 2015 and 2014 represented 51% and 26% of gross revenues, respectively. The increase in the contractual allowances is due to changes in our estimates of net revenue for non-contracted payors based on the contractual status and payment policies of the payors, and anticipated changes in the healthcare industry.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation
	Compensation expense for all stock-based payments made to employees, directors, and consultants are measured and recognized based on estimated fair value, net of an estimated forfeiture rate. These stock-based awards include stock options and restricted stock units. The Company estimates the fair value of stock options granted using the Black-Scholes-Merton (“BSM”), option-pricing model, which requires the use of estimates such as stock price volatility and expected option lives, as well as expected option forfeiture rates. The fair value of stock options granted to employees is estimated at the date of grant, while the fair value of stock options granted to non-employees is estimated at the date of grant using the BSM pricing model and remeasured at each subsequent reporting date to fair value until performance is complete, with changes in fair value recognized as expense in the statement of operations.
	The fair value of restricted stock units issued to employees is based on the market price of the Company’s common stock on the date of grant and, for nonemployees, at the date when performance is complete. Upon settlement of all or a portion of the award in cash, the recognized fair value of the corresponding amount of awards is reversed from additional paid-in capital and the excess of the cash payment over this amount is recognized as additional stock-based compensation expense.
	Stock-based compensation cost is recognized on a straight-line basis over the requisite service period of the award. Stock-based compensation expense is recognized only for those awards that are ultimately expected to vest. The Company estimates forfeitures at the time of grant and revises the estimate, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Changes in forfeiture estimates impact compensation cost in the period in which the change in estimate occurs.
	Due to the Company’s net loss position, no tax benefits for stock-based compensation have been recognized in the statements of cash flows. The Company has not recognized, and does not expect to recognize in the near future, any tax benefit related to stock-based compensation cost as a result of its full valuation allowance on net deferred tax assets and net operating loss carryforwards.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments
	The Company’s financial instruments that are measured at fair value on a recurring basis consist principally of cash, restricted cash, accounts receivable and accounts payable
	The carrying amounts of financial instruments such as accounts receivable and accounts payable approximate their relative fair values due to the short-term maturities of these instruments.
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
	Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
	Level 2—Includes other inputs that are directly or indirectly observable in the marketplace.
	Level 3—Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own assumptions.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share
	Basic and diluted net loss per common share for the periods presented is computed by dividing net loss by the weighted-average number of common shares outstanding during the respective periods, without consideration of common stock equivalents. Basic and diluted net loss per common share includes vested, but unissued restricted stock units from the date of vesting.
	Common stock equivalents that could potentially reduce net income per common share in the future that were not included in the determination of diluted loss per common share as their effects were antidilutive are as follows:
		March 31,
		2015
	Unvested restricted stock units		527,934
	Options to purchase common stock		180,000
	Warrants to purchase common stock		203,214
	Total		911,148
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk, Major Customers and Suppliers
	Cash is maintained at two financial institutions and, at times, balances may exceed federally insured limits. The Company has not experienced any losses related to these balances.
	During the three months ended March 31, 2015 and 2014, the Company had one major customer, UAMS. Revenue sourced either from or through UAMS accounted for 77% and 79% of net revenue during the three months ended March 31, 2015 and 2014, respectively. Accounts receivable sourced either from or through UAMS at March 31, 2015 and December 31, 2014 accounted for 58% and 63% of total accounts receivable outstanding, respectively.
	Inventory used in the Company’s testing process is procured from one supplier. Any supply interruption or an increase in demand beyond such supplier’s capabilities could have an adverse impact on the Company’s business. Management believes it could identify alternative suppliers, if necessary, but it is possible such suppliers may not be identified in a timely manner to avoid an adverse impact on the Company’s business.
Reclassification, Policy [Policy Text Block]	Reclassifications
	Reclassifications of certain operating expenses in the consolidated statement of operations have been made as of and during the three months ended March 31, 2014 to conform to the 2015 presentation.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements
	In February 2015, the Financial Accounting Standards Board (“FASB”) issued amendments to Accounting Standards Update (“ASU”) 2015-02, Consolidation: Amendments to the Consolidation Analysis. This standard simplifies consolidation accounting by reducing the number of consolidation models and changing various aspects of current GAAP, including certain consolidation criteria for variable interest entities. This standard becomes effective for the Company’s first quarter beginning January 1, 2017 with early adoption permitted. Upon adoption, the Company may elect prospective or retrospective application. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
	In January 2015, the FASB issued ASU 2015-01, Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items. Under this standard, an entity will no longer be allowed to separately disclose extraordinary items, net of tax, in the income statement after income from continuing operations if an event or transaction is unusual in nature and occurs infrequently. This standard becomes effective for the Company’s first quarter beginning January 1, 2016 with early adoption permitted. Upon adoption, the Company may elect prospective or retrospective application. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which outlines a single comprehensive model for entities to use in accounting for revenue from contracts with customers and supersedes most current revenue recognition guidance in FASB ASC 605, Revenue Recognition, including industry-specific guidance. This standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This standard also requires additional disclosure about the nature, amount, timing and uncertainty of assets recognized from costs incurred to fulfill a contract and becomes effective for the Company’s annual reporting period beginning January 1, 2019, including interim periods within that reporting period; early adoption is not permitted. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements — Going Concern, which provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and the related footnote disclosure. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financials are issued. When management identifies conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern, this standard also outlines disclosures that are required in the company’s footnotes based on whether or not there are any plans intended to mitigate the relevant conditions or events to alleviate the substantial doubt. This standard becomes effective for the Company’s annual reporting period ending December 31, 2016, and for annual and interim periods thereafter. Early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

Note_2_Significant_Accounting_1

Note 2 - Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Reconciliation Of Gross Revenues To Net Revenues [Table Text Block]	The table below shows the adjustments made to gross revenues to arrive at net revenues, the amount reported in the consolidated statements of operations:
		Three Months Ended March 31,
	(in thousands)	2015			2014
	Gross revenues	$	1,317		$	1,484
	Less: contractual allowances		(672	)		(393	)
	Net revenue	$	645		$	1,091
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Common stock equivalents that could potentially reduce net income per common share in the future that were not included in the determination of diluted loss per common share as their effects were antidilutive are as follows:
		March 31,
		2015
	Unvested restricted stock units		527,934
	Options to purchase common stock		180,000
	Warrants to purchase common stock		203,214
	Total		911,148

Note_3_Balance_Sheet_Accounts_1

Note 3 - Balance Sheet Accounts and Supplemental Disclosures (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block Supplement [Abstract]
Property, Plant and Equipment [Table Text Block]	(in thousands)	March 31,			31-Dec-14
		2015
	Laboratory and computer equipment	$	1,745		$	1,711
	Furniture and fixtures		62			52
	Leasehold improvements		6			6
			1,813			1,769
	Less: accumulated depreciation and amortization		(600	)		(555	)
	Total property and equipment, net	$	1,213		$	1,214
Schedule of Accrued Liabilities [Table Text Block]	(in thousands)	March 31,			31-Dec-14
		2015
	Accrued compensation and related expenses	$	483		$	257
	Accrued offering costs		225			42
	Other		95			62
	Total accrued expenses	$	803		$	361

Note_5_Stockholders_Equity_Tab

Note 5 - Stockholders’ Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule of Stockholders Equity [Table Text Block]		Shares of Common Stock			Total Stockholders’ Equity
					(in thousands)
	Balance, December 31, 2014		3,782,629		$	5,991
	Public offering of common shares, net of costs to issue		3,696,427			8,781
	Fair value of warrants and option to underwriters for overallotment shares issued in connection with public stock offering		—			330
	Stock-based compensation		—			708
	Shares issued under employee stock incentive plan, net of shares withheld to satisfy tax withholding obligations		25,934			(27	)
	Net loss		—			(2,634	)
	Balance, March 31, 2015		7,504,990		$	13,149
Schedule of Common Stock Shares Reserved For Future Issuance [Table Text Block]	Issued and Outstanding:
	Restricted stock units		903,704
	Stock options		180,000
	Warrants		203,214
	Shares reserved for future award grants		135,761
	Total		1,422,679
Schedule of Share-based Payment Award, Nonemployee, Valuation Assumptions [Table Text Block]		Warrants			Overallotment Option
	Fair value of underlying common stock	$	2.57		$	2.62
	Exercise price	$	3.5		$	2.6
	Risk-free interest rate		1.61	%		0.02	%
	Volatility		65.5	%		73	%
	Dividend Yield		0	%		0	%
	Contractual term (in years)		5			0.12
	Weighted-average measurement date fair value per share	$	1.23		$	0.27

Note_6_Stock_Compensation_Plan1

Note 6 - Stock Compensation Plan (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]		Number of Shares			Weighted-Average Grant Date Fair Value per Share
	Unvested at December 31, 2014		655,200		$	9.2
	Vested during the period		(127,266	)	$	10
	Unvested at March 31, 2015		527,934		$	9.01
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]		Shares Subject to Options			Weighted-Average Exercise Price per Share		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value
							(in years)		(in thousands)
	Outstanding at December 31, 2014		152,000		$	4.53
	Granted		29,000		$	2.44
	Forfeitures and cancellations		(1,000	)	$	5.6
	Outstanding at March 31, 2015		180,000		$	4.19		3.5	$	—
	Options exercisable at March 31, 2015		—		$	—		—	$	—
	Options vested or expected to vest at March 31, 2015		173,879		$	4.19		3.5	$	—
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Risk-free interest rate	1.34%	-	1.83%
	Expected volatility	65.30%	-	67.80%
	Weighted-average volatility		65.90%
	Dividend yield		0%
	Expected term (in years)		6.3
	Weighted-average grant date fair value per share		$1.49
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	(in thousands)
	Cost of revenue	$	22
	Research and development		16
	Selling and marketing		11
	General and administrative		659
	Total	$	708

Note_1_Basis_of_Presentation_D

Note 1 - Basis of Presentation (Details) (USD $)	0 Months Ended		3 Months Ended		0 Months Ended
	Feb. 20, 2015	Jun. 17, 2014	Mar. 31, 2015	Mar. 31, 2014	Feb. 26, 2015	Jun. 23, 2014
Note 1 - Basis of Presentation (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)	3,214,285		3,696,427
Share Price (in Dollars per share)	$2.80
Proceeds from Issuance of Common Stock	$7,900,000		$9,346,000	($274,000)
Payments of Stock Issuance Costs	1,100,000
Debt Conversion, Original Debt, Amount		27,300,000
Stock Issued During Period, Shares, Conversion of Units (in Shares)		2,932,629
Adjustments to Additional Paid in Capital, Other	8,800,000
Overallotment Option [Member] | Underwriter Options [Member]
Note 1 - Basis of Presentation (Details) [Line Items]
Payments of Stock Issuance Costs					95,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)					482,142
Proceeds from Stock Options Exercised					1,300,000
IPO [Member]
Note 1 - Basis of Presentation (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)						850,000
Share Price (in Dollars per share)						$10
Payments of Stock Issuance Costs						2,400,000
Proceeds from Issuance Initial Public Offering						6,100,000
Adjustments to Additional Paid in Capital, Other						$5,800,000
Conversion of Class A Units [Member]
Note 1 - Basis of Presentation (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Units (in Shares)		200,000
Conversion of Class C Units [Member]
Note 1 - Basis of Presentation (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Units (in Shares)		2,732,629
Underwriter Options [Member]
Note 1 - Basis of Presentation (Details) [Line Items]
Share Price (in Dollars per share)			$2.62
Capital Unit, Class C [Member]
Note 1 - Basis of Presentation (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)		2,732,629

Note_2_Significant_Accounting_2

Note 2 - Significant Accounting Policies (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Note 2 - Significant Accounting Policies (Details) [Line Items]
Provision for Doubtful Accounts	$24,000	$0
Allowance for Doubtful Accounts Receivable	20,000		0
Deferred Finance Costs, Noncurrent, Gross			47,000
Contractual Allowances Percentage	51.00%	26.00%
Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options	0
Number Of Major Suppliers	1
Letter of Credit [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Restricted Cash and Cash Equivalents, Current	50,000		50,000
UAMS [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage	77.00%	79.00%
UAMS [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage	58.00%		63.00%
Sales Returns and Allowances [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Estimated Non-contracted Revenues, Adjustment	$30,000
Customer Concentration Risk [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Number Of Major Customers	1		1

Note_2_Significant_Accounting_3

Note 2 - Significant Accounting Policies (Details) - Adjustments Made to Gross Revenues to Arrive at Net Revenues (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Adjustments Made to Gross Revenues to Arrive at Net Revenues [Abstract]
Gross revenues	$1,317	$1,484
Less: contractual allowances	-672	-393
Net revenue	$645	$1,091

Note_2_Significant_Accounting_4

Note 2 - Significant Accounting Policies (Details) - Antidilutive Securities Excluded from Earnings Per Share	3 Months Ended
	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	911,148
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	527,934
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	180,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	203,214

Note_3_Balance_Sheet_Accounts_2

Note 3 - Balance Sheet Accounts and Supplemental Disclosures (Details) (Laboratory and Computer Equipment [Member], USD $)	Mar. 31, 2015	Dec. 31, 2014
Laboratory and Computer Equipment [Member]
Note 3 - Balance Sheet Accounts and Supplemental Disclosures (Details) [Line Items]
Capital Leased Assets, Gross	$300,000	$300,000

Note_3_Balance_Sheet_Accounts_3

Note 3 - Balance Sheet Accounts and Supplemental Disclosures (Details) - Property and Equipment (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Property and equipment	$1,813	$1,769
	1,813	1,769
Less: accumulated depreciation and amortization	-600	-555
Total property and equipment, net	1,213	1,214
Laboratory and Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	1,745	1,711
	1,745	1,711
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	62	52
	62	52
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	6	6
	$6	$6

Note_3_Balance_Sheet_Accounts_4

Note 3 - Balance Sheet Accounts and Supplemental Disclosures (Details) - Accrued Expenses (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Accrued Expenses [Abstract]
Accrued compensation and related expenses	$483	$257
Accrued offering costs	225	42
Other	95	62
Total accrued expenses	$803	$361

Note_4_Note_Payable_Related_Pa1

Note 4 - Note Payable - Related Party, Amount Due Related Party and Capital Lease Obligations (Details) (USD $)	0 Months Ended	3 Months Ended		12 Months Ended	0 Months Ended
	Jun. 17, 2014	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Mar. 06, 2015
Note 4 - Note Payable - Related Party, Amount Due Related Party and Capital Lease Obligations (Details) [Line Items]
Debt Conversion, Original Debt, Amount	$27,300,000
Notes Payable, Related Parties, Current		1,058,000
Interest Expense, Related Party		19,000
Proceeds from Related Party Debt			100,000
Capital Lease Obligation, Term				2 years
Capital Lease Obligations, Monthly Rent				7,200
Capital Lease Obligations		148,000		164,000
Capital Lease Obligation, Unamortized Discount		7,000		8,000
Capital Leases, Future Minimum Payments Due, Next Twelve Months		65,000
Capital Leases, Future Minimum Payments Due in Two Years		86,000
Capital Leases, Future Minimum Payments Due in Three Years		4,000
Majority Shareholder [Member] | Interest Rate Compounded Quarterly [Member]
Note 4 - Note Payable - Related Party, Amount Due Related Party and Capital Lease Obligations (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			8.00%
Majority Shareholder [Member]
Note 4 - Note Payable - Related Party, Amount Due Related Party and Capital Lease Obligations (Details) [Line Items]
Interest Expense, Related Party			532,000
Proceeds from Related Party Debt			100,000
Short-term Debt, Average Outstanding Amount			26,900,000
Due to Related Party Converted to Unsecured Note Payable [Member]
Note 4 - Note Payable - Related Party, Amount Due Related Party and Capital Lease Obligations (Details) [Line Items]
Debt Conversion, Original Debt, Amount					1,045,000
Debt Instrument, Interest Rate, Stated Percentage					8.00%
Debt Instrument, Increase (Decrease), Net					60,000
Notes Payable, Related Parties, Current		1,058,000			1,105,000
Related Party Transaction, Rate					8.00%
Debt Instrument, Unamortized Discount		$47,000

Note_5_Stockholders_Equity_Det

Note 5 - Stockholders’ Equity (Details) (USD $)	0 Months Ended	3 Months Ended		0 Months Ended
	Feb. 20, 2015	Mar. 31, 2015	Mar. 31, 2014	Feb. 26, 2015	Dec. 31, 2014
Note 5 - Stockholders’ Equity (Details) [Line Items]
Common Stock, Shares Authorized (in Shares)		50,000,000			50,000,000
Common Stock, Shares, Issued (in Shares)		7,504,990			3,782,629
Stock Issued During Period, Shares, New Issues (in Shares)	3,214,285	3,696,427
Share Price (in Dollars per share)	$2.80
Proceeds from Issuance of Common Stock	$7,900,000	$9,346,000	($274,000)
Payments of Stock Issuance Costs	1,100,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	160,713
Issuance of Stock and Warrants for Services or Claims	198,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$3.50
Adjustments to Additional Paid in Capital, Other	8,800,000
Over-Allotment Option [Member] | Underwriter Options [Member]
Note 5 - Stockholders’ Equity (Details) [Line Items]
Payments of Stock Issuance Costs				95,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)				482,142
Proceeds from Stock Options Exercised				1,300,000
Underwriter Options [Member]
Note 5 - Stockholders’ Equity (Details) [Line Items]
Share Price (in Dollars per share)		$2.62
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	45 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$132,000

Note_5_Stockholders_Equity_Det1

Note 5 - Stockholders’ Equity (Details) - Changes in Common Shares Outstanding and Total Stockholders' Equity (USD $)	0 Months Ended	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Feb. 20, 2015	Mar. 31, 2015	Mar. 31, 2014
Changes in Common Shares Outstanding and Total Stockholders' Equity [Abstract]
Shares of Common Stock (in Shares)		3,782,629
Total Stockholders’ Equity		$5,991
Public offering of common shares, net of costs to issue (in Shares)	3,214,285	3,696,427
Public offering of common shares, net of costs to issue		8,781
Fair value of warrants and option to underwriters for overallotment shares issued in connection with public stock offering		330
Stock-based compensation		708
Shares issued under employee stock incentive plan, net of shares withheld to satisfy tax withholding obligations (in Shares)		25,934
Shares issued under employee stock incentive plan, net of shares withheld to satisfy tax withholding obligations		-27
Net loss		-2,634	-706
Shares of Common Stock (in Shares)		7,504,990
Total Stockholders’ Equity		$13,149

Note_5_Stockholders_Equity_Det2

Note 5 - Stockholders’ Equity (Details) - Common Shares Reserved for Future Issuance	Mar. 31, 2015	Dec. 31, 2014
Issued and Outstanding:
Stock options	180,000	152,000
Shares reserved for future award grants	135,761
Total	1,422,679
Restricted Stock Units (RSUs) [Member]
Issued and Outstanding:
Restricted stock units	903,704
Employee Stock Option [Member]
Issued and Outstanding:
Stock options	180,000
StockWarrants [Member]
Issued and Outstanding:
Warrants	203,214

Note_5_Stockholders_Equity_Det3

Note 5 - Stockholders’ Equity (Details) - BSM Option Valuation Model Assumptions (USD $)	3 Months Ended
	Mar. 31, 2015	Feb. 20, 2015
Note 5 - Stockholders’ Equity (Details) - BSM Option Valuation Model Assumptions [Line Items]
Fair value of underlying common stock		$2.80
Warrant [Member]
Note 5 - Stockholders’ Equity (Details) - BSM Option Valuation Model Assumptions [Line Items]
Fair value of underlying common stock	$2.57
Exercise price	$3.50
Risk-free interest rate	1.61%
Volatility	65.50%
Dividend Yield	0.00%
Contractual term (in years)	5 years
Weighted-average measurement date fair value per share	$1.23
Underwriter Options [Member]
Note 5 - Stockholders’ Equity (Details) - BSM Option Valuation Model Assumptions [Line Items]
Fair value of underlying common stock	$2.62
Exercise price	$2.60
Risk-free interest rate	0.02%
Volatility	73.00%
Dividend Yield	0.00%
Contractual term (in years)	43 days
Weighted-average measurement date fair value per share	$0.27

Note_6_Stock_Compensation_Plan2

Note 6 - Stock Compensation Plan (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Note 6 - Stock Compensation Plan (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	135,761
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeiture Rate	1.90%
Restricted Stock Units (RSUs) [Member] | Minimum [Member] | The Plan [Member]
Note 6 - Stock Compensation Plan (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year
Restricted Stock Units (RSUs) [Member] | Maximum [Member] | The Plan [Member]
Note 6 - Stock Compensation Plan (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Restricted Stock Units (RSUs) [Member] | The Plan [Member]
Note 6 - Stock Compensation Plan (Details) [Line Items]
Shares Paid for Tax Withholding for Share Based Compensation (in Shares)	10,455
Adjustments Related to Tax Withholding for Share-based Compensation (in Dollars)	27,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)	3,600,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 292 days
Restricted Stock Units (RSUs) [Member]
Note 6 - Stock Compensation Plan (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value (in Dollars)	322,000
Employee Stock Option [Member] | The Plan [Member]
Note 6 - Stock Compensation Plan (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years 6 months
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)	407,000
The Plan [Member]
Note 6 - Stock Compensation Plan (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)	1,219,465
Share-based Compensation Arrangement by Share-based Payment Award, Number of Awards Outstanding (in Shares)	1,083,704
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	135,761

Note_6_Stock_Compensation_Plan3

Note 6 - Stock Compensation Plan (Details) - Restricted Stock Units Activity (Restricted Stock Units (RSUs) [Member], USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 30, 2014
Restricted Stock Units (RSUs) [Member]
Note 6 - Stock Compensation Plan (Details) - Restricted Stock Units Activity [Line Items]
Unvested at December 31, 2014		655,200
Unvested at December 31, 2014		$9.20
Vested during the period	-127,266
Vested during the period	$10
Unvested at March 31, 2015	527,934	655,200
Unvested at March 31, 2015	$9.01	$9.20

Note_6_Stock_Compensation_Plan4

Note 6 - Stock Compensation Plan (Details) - Stock Options Activity (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Stock Options Activity [Abstract]
Shares Subject to Options	180,000	152,000
Weighted-Average Exercise Price per Share	$4.19	$4.53
Weighted-Average Remaining Contractual Term (in years)	3 years 6 months
Granted	29,000
Granted	$2.44
Forfeitures and cancellations	-1,000
Forfeitures and cancellations	$5.60
Options vested or expected to vest at March 31, 2015	173,879
Options vested or expected to vest at March 31, 2015	$4.19
Options vested or expected to vest at March 31, 2015	3 years 6 months

Note_6_Stock_Compensation_Plan5

Note 6 - Stock Compensation Plan (Details) - BSM Option Valuation Model Assumptions (Employee Stock Option [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Note 6 - Stock Compensation Plan (Details) - BSM Option Valuation Model Assumptions [Line Items]
Weighted-average volatility	65.90%
Dividend yield	0.00%
Expected term (in years)	6 years 109 days
Weighted-average grant date fair value per share (in Dollars per share)	1.49
Minimum [Member]
Note 6 - Stock Compensation Plan (Details) - BSM Option Valuation Model Assumptions [Line Items]
Risk-free interest rate	1.34%
Expected volatility	65.30%
Maximum [Member]
Note 6 - Stock Compensation Plan (Details) - BSM Option Valuation Model Assumptions [Line Items]
Risk-free interest rate	1.83%
Expected volatility	67.80%

Note_6_Stock_Compensation_Plan6

Note 6 - Stock Compensation Plan (Details) - Stock-based Compensation Expense Allocation (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	$708
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	22
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	16
Selling and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	11
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	$659